The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis
Abstract
Objective: To assess the association between the initiation of anti–tumor necrosis factor α (anti‐TNFα) therapy and the risk of serious bacterial infections in routine care. Methods: This was a cohort study of patients with rheumatoid arthritis (RA) in whom specific disease‐modifying antirheumatic drugs (DMARDs) were initiated. Patients were Medicare beneficiaries ages 65 years and older (mean age 76.5 years) who were concurrently enrolled in the Pharmaceutical Assistance Contract for the Elderly provided by the state of Pennsylvania. A total of 15,597 RA patients in whom a DMARD was initiated between January 1, 1995 and December 31, 2003 were identified using linked data on all prescription drug dispensings, physician services, and hospitalizations. Initiation of anti‐TNFα therapy, cytotoxic agents other than methotrexate (MTX), noncytotoxic agents, and glucocorticoids was compared with initiation of MTX. The main outcome measure was serious bacterial infections that required hospitalization. Results: The incidence of serious bacterial infections was, on average, 2.2 per 100 patient‐years in this population (95% confidence interval [95% CI] 2.0–2.4). Glucocorticoid use doubled the rate of serious bacterial infections as compared with MTX use, independent of previous DMARD use (rate ratio [RR] 2.1 [95% CI 1.5–3.1]), with a clear dose‐response relationship for dosages >5 mg/day (for ≤5 mg/day, RR 1.34; for 6–9 mg/day, RR 1.53; for 10–19 mg/day, RR 2.97; and for ≥20 mg/day, RR 5.48 [P for trend < 0.0001]). Adjusted models showed no increase in the rate of serious infections among initiators of anti‐TNFα therapy (RR 1.0 [95% CI 0.6–1.7]) or other DMARDs as compared with initiators of MTX. Conclusion: In a large cohort of patients with RA, we found no increase in serious bacterial infections among users of anti‐TNFα therapy compared with users of MTX. Glucocorticoid use was associated with a dose‐dependent increase in such infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Romano, P. S., Roos, L. L., & Jollis, J. G. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90103-8 · Cited by 1,717
Methods in Observational Epidemiology
Kelsey, J. L. (1986) · Cited by 1,307
Methods in observational epidemiology
Leck, I. (1987) · Journal of Epidemiology and Community Health · doi:10.1136/jech.41.3.263-a · Cited by 1,278
A review of uses of health care utilization databases for epidemiologic research on therapeutics
Schneeweiss, S., & Avorn, J. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.012 · Cited by 1,277
Self-citationDoran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10524 · Cited by 1,214
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Gavazzi, G., & Krause, K.-H. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00437-1 · Cited by 990
Cepeda, M. S. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg115 · Cited by 859
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
Gardam, M. A., Keystone, E. C., Menzies, R., Manners, S., Skamene, E., Long, R., & Vinh, D. C. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00545-0 · Cited by 752
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Schneeweiss, S. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1200 · Cited by 727
Self-citationSchneeweiss, S. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.9.854 · Cited by 711
Self-citationInfections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Carmona, L., Gómez‐Reino, J. J., Rodríguez‐Valverde, V., Montero, D., Pascual‐Gómez, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21043 · Cited by 656
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Predictors of infection in rheumatoid arthritis
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10529 · Cited by 560
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Wolfe, F., Caplan, L., & Michaud, K. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21568 · Cited by 480
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Slifman, N. R., Gershon, S. K., Lee, J., Edwards, E. T., & Braun, M. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10758 · Cited by 383
Rare Outcomes, Common Treatments: Analytic Strategies Using Propensity Scores
Braitman, L. E., & Rosenbaum, P. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00015 · Cited by 364
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
Infections and anti–tumor necrosis factor α therapy
Ellerin, T., Rubin, R. H., & Weinblatt, M. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11301 · Cited by 284
Self-citationGaps in care for rheumatoid arthritis: A population study
Lacaille, D., Anis, A. H., Guh, D. P., & Esdaile, J. M. (2005) · Arthritis Care & Research · doi:10.1002/art.21077 · Cited by 225
Veteran’s affairs hospital discharge databases coded serious bacterial infections accurately
Schneeweiss, S., Robicsek, A., Scranton, R., Zuckerman, D., & Solomon, D. H. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.07.011 · Cited by 178
Self-citationvan de Putte, L. B. A., Rau, R., Breedveld, F. C., Kalden, J. R., Malaise, M. G., van Riel, P. L. C. M., Schattenkirchner, M., Emery, P., Burmester, G. R., Zeidler, H., et al. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.009563 · Cited by 176
Fatal Sepsis in a Patient With Rheumatoid Arthritis Treated With Etanercept
Baghai, M., Osmon, D. R., Wolk, D. M., Wold, L. E., Haidukewych, G. J., & Matteson, E. L. (2001) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62418-x · Cited by 166
Co-morbidity in rheumatoid arthritis
Mikuls, T. R. (2003) · Best Practice & Research Clinical Rheumatology · doi:10.1016/s1521-6942(03)00041-x · Cited by 122
Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.
Long, R., & Gardam, M. A. (2003) · PubMed · Cited by 88
Small-sample bias and corrections for conditional maximum-likelihood odds-ratio estimators
Greenland, S. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.113 · Cited by 88
Schneeweiß, S., Wang, P. S., Avorn, J., Maclure, M., Levin, R., & Glynn, R. J. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30109.x · Cited by 81
Self-citationMcMahon, A. D., Evans, J. M. M., McGilchrist, M. M., McDevitt, D. G., & MacDonald, T. M. (1998) · Pharmacoepidemiology and Drug Safety · Cited by 37
Cited by
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Gabriel, S. E., & Michaud, K. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2669 · Cited by 891
Galloway, J. B., Hyrich, K. L., Mercer, L. K., Dixon, W. G., Fu, B., Ustianowski, A. P., Watson, K. D., Lunt, M., BSRBR Control Centre Consortium, Symmons, D. P. M., et al. (2011) · Rheumatology · doi:10.1093/rheumatology/keq242 · Cited by 676
Singh, J. A., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., Ghogomu, E. T., Coyle, D., Clifford, T., Tugwell, P., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61704-9 · Cited by 623
Metadata
- Authors
- Schneeweiss, S., Setoguchi, S., Weinblatt, M. E., Katz, J. N., Avorn, J., Sax, P. E., Levin, R., & Solomon, D. H.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-05-25
- Volume
- 56
- Issue
- 6
- Pages
- 1754-1764
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1984181327
- Cited by
- 302
- References
- 40
- FWCI
- 19.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.